MorphoSys AG
MOR · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.05 | -0.03 | -0.02 |
| FCF Yield | -2.54% | -4.02% | -4.07% | -13.47% |
| EV / EBITDA | -10.12 | 70.42 | -19.11 | -25.24 |
| Quality | ||||
| ROIC | -19.49% | -4.75% | -2.77% | -3.76% |
| Gross Margin | 85.96% | 75.36% | 76.33% | 85.51% |
| Cash Conversion Ratio | 0.21 | -1.17 | 0.28 | 1.70 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.40% | 9.91% | 17.06% | 26.86% |
| Free Cash Flow Growth | -13.03% | -61.44% | 71.97% | -75.93% |
| Safety | ||||
| Net Debt / EBITDA | -0.49 | 17.73 | -1.88 | -2.37 |
| Interest Coverage | -93.30 | 0.00 | -0.76 | -1.78 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.23 | 0.21 | 0.11 |
| Cash Conversion Cycle | -1,721.96 | 273.24 | -234.21 | -416.09 |